Gerilimzumab - argenx

Drug Profile

Gerilimzumab - argenx

Alternative Names: ARGX 109; GB 224; RYI 008

Latest Information Update: 08 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator arGEN-X
  • Developer argenx; Bird Rock Bio; Genor Biopharma
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin-6 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • No development reported Autoimmune disorders; Cancer; Ovarian cancer; Renal cell carcinoma

Most Recent Events

  • 01 Mar 2018 argenx terminates its licence for ARGX 109 in USA
  • 01 Nov 2017 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in China (SC) (ChiCTR-IIR17013205)
  • 03 Jan 2017 ANVISA and CONEP grant approval for conducting a phase II trial for Rheumatoid arthritis in Brazil
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top